明德生物
(002932)
| 流通市值：30.34亿 | | | 总市值：45.20亿 |
| 流通股本：1.56亿 | | | 总股本：2.33亿 |
| 报告期 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 流动资产: | | | | |
| 货币资金 | 352,691,446.01 | 493,911,960.04 | 494,486,276.36 | 778,450,496.23 |
| 结算备付金 | - | - | 0 | - |
| 拆出资金 | - | - | 0 | - |
| 衍生金融资产 | - | - | 0 | - |
| 应收票据及应收账款 | 714,286,789.61 | 764,653,472.04 | 902,012,394.53 | 990,729,494.56 |
| 其中：应收票据 | - | 212,057.7 | 0 | 572,860.8 |
| 应收账款 | 714,286,789.61 | 764,441,414.34 | 902,012,394.53 | 990,156,633.76 |
| 应收款项融资 | - | 2,298,274 | 0 | - |
| 预付款项 | 58,914,503.09 | 49,040,683.23 | 80,902,727 | 85,746,381.02 |
| 应收保费 | - | - | 0 | - |
| 应收分保账款 | - | - | 0 | - |
| 应收分保合同准备金 | - | - | 0 | - |
| 其他应收款合计 | 11,487,110.89 | 6,608,204.3 | 9,378,957.97 | 10,268,575.19 |
| 其中:应收利息 | - | - | 0 | - |
| 应收股利 | - | - | 0 | - |
| 买入返售金融资产 | - | - | 0 | - |
| 存货 | 76,064,673.86 | 82,298,479.51 | 120,512,276.15 | 123,502,007.66 |
| 合同资产 | - | - | 0 | - |
| 一年内到期的非流动资产 | 2,807,559,097.22 | 738,792,375 | 320,511,875 | 204,990,972.22 |
| 其他流动资产 | 221,797,704.24 | 195,951,542.38 | 129,849,776.3 | 127,140,642.71 |
| 流动资产平衡项目 | 0 | 0 | 0 | 0 |
| 流动资产合计 | 4,306,916,741.27 | 2,397,670,406.85 | 2,120,880,457.63 | 2,384,054,743.91 |
| 非流动资产: | | | | |
| 发放委托贷款及垫款 | - | - | 0 | - |
| 债权投资 | - | - | 0 | - |
| 其他债权投资 | - | - | 0 | - |
| 长期应收款 | - | - | 0 | - |
| 长期股权投资 | 306,106,981.95 | 247,606,981.95 | 145,456,069.38 | 145,456,069.39 |
| 其他权益工具投资 | 10,000,000 | 10,000,000 | 10,000,000 | 10,000,000 |
| 其他非流动金融资产 | - | - | 0 | - |
| 投资性房地产 | - | - | 0 | - |
| 固定资产 | 579,391,901.41 | 592,140,876.69 | 298,032,831.63 | 309,797,015.23 |
| 在建工程 | 148,729,557.84 | 120,787,956.73 | 447,115,145.95 | 280,200,385.92 |
| 生产性生物资产 | - | - | 0 | - |
| 油气资产 | - | - | 0 | - |
| 使用权资产 | 8,242,504.47 | 8,751,913.62 | 21,904,432.67 | 22,399,496.42 |
| 无形资产 | 17,073,045.91 | 17,303,449.78 | 16,936,213.59 | 17,147,669.26 |
| 开发支出 | - | - | 0 | - |
| 商誉 | - | - | 0 | - |
| 长期待摊费用 | 2,833,778.91 | 3,105,493.38 | 12,910,136.92 | 12,746,870.9 |
| 递延所得税资产 | 214,678,342.39 | 216,900,753.86 | 204,332,910.84 | 209,431,974.49 |
| 其他非流动资产 | 905,429,207.48 | 2,978,810,763.04 | 3,552,372,983.81 | 3,542,187,778.51 |
| 非流动资产平衡项目 | 0 | 0 | 0 | 0 |
| 非流动资产合计 | 2,192,485,320.36 | 4,195,408,189.05 | 4,709,060,724.79 | 4,549,367,260.12 |
| 资产平衡项目 | 0 | 0 | 0 | 0 |
| 资产总计 | 6,499,402,061.63 | 6,593,078,595.9 | 6,829,941,182.42 | 6,933,422,004.03 |
| 流动负债: | | | | |
| 短期借款 | 3,000,000 | 3,000,000 | 3,000,000 | 3,000,000 |
| 向中央银行借款 | - | - | 0 | - |
| 吸收存款及同业存放 | - | - | 0 | - |
| 拆入资金 | - | - | 0 | - |
| 交易性金融负债 | - | - | 0 | - |
| 衍生金融负债 | - | - | 0 | - |
| 应付票据及应付账款 | 248,241,215.03 | 278,113,513.57 | 409,435,487.94 | 493,311,071.46 |
| 其中：应付票据 | - | - | 20,742,916.65 | 20,742,916.65 |
| 应付账款 | 248,241,215.03 | 278,113,513.57 | 388,692,571.29 | 472,568,154.81 |
| 预收款项 | - | - | 0 | - |
| 合同负债 | 40,049,058.89 | 37,963,618.82 | 40,586,997.18 | 43,460,999.23 |
| 卖出回购金融资产款 | - | - | 0 | - |
| 应付手续费及佣金 | - | - | 0 | - |
| 应付职工薪酬 | 70,182,245.14 | 87,084,064.89 | 106,121,783.84 | 107,950,498.86 |
| 应交税费 | 5,166,659.92 | 8,249,223.74 | 10,633,453.42 | 13,360,814.03 |
| 其他应付款合计 | 43,833,833 | 67,256,648.85 | 65,477,088.68 | 59,638,434.06 |
| 其中:应付利息 | - | - | 0 | - |
| 应付股利 | - | - | 0 | - |
| 应付分保账款 | - | - | 0 | - |
| 保险合同准备金 | - | - | 0 | - |
| 代理买卖证券款 | - | - | 0 | - |
| 代理承销证券款 | - | - | 0 | - |
| 一年内到期的非流动负债 | 4,296,271.73 | 4,296,271.73 | 8,155,867.48 | 8,155,867.48 |
| 其他流动负债 | 6,709,505.02 | 9,893,196.08 | 1,761,232.22 | 1,982,161 |
| 流动负债平衡项目 | 0 | 0 | 0 | 0 |
| 流动负债合计 | 421,478,788.73 | 495,856,537.68 | 645,171,910.76 | 730,859,846.12 |
| 非流动负债: | | | | |
| 长期借款 | - | - | 0 | - |
| 应付债券 | - | - | 0 | - |
| 优先股 | - | - | 0 | - |
| 永续债 | - | - | 0 | - |
| 租赁负债 | 5,526,201.58 | 5,816,561.4 | 16,692,328.68 | 16,969,263.61 |
| 长期应付款 | - | - | 0 | - |
| 长期应付职工薪酬 | - | - | 0 | - |
| 预计负债 | 1,440,500 | 1,440,500 | 3,848,640.25 | 3,033,517.6 |
| 递延收益 | 20,866,000 | 20,866,000 | 14,260,000 | 14,260,000 |
| 递延所得税负债 | 50,421,556.8 | 50,421,556.8 | 39,646,145.82 | 39,646,145.82 |
| 其他非流动负债 | - | - | 0 | - |
| 非流动负债平衡项目 | 0 | 0 | 0 | 0 |
| 非流动负债合计 | 78,254,258.38 | 78,544,618.2 | 74,447,114.75 | 73,908,927.03 |
| 负债平衡项目 | 0 | 0 | 0 | 0 |
| 负债合计 | 499,733,047.11 | 574,401,155.88 | 719,619,025.51 | 804,768,773.15 |
| 所有者权益(或股东权益): | | | | |
| 实收资本(或股本) | 232,520,957 | 232,520,957 | 232,520,957 | 232,520,957 |
| 其他权益工具 | - | - | 0 | - |
| 优先股 | - | - | 0 | - |
| 永续债 | - | - | 0 | - |
| 资本公积 | 818,099,532.65 | 818,099,532.65 | 817,891,388.45 | 817,891,388.45 |
| 减:库存股 | 247,957,340 | 237,954,376.7 | 182,108,715.49 | 162,874,596 |
| 其他综合收益 | - | - | 0 | - |
| 专项储备 | - | - | 0 | - |
| 盈余公积 | 630,728,262.08 | 630,728,262.08 | 615,047,764.7 | 615,047,764.7 |
| 一般风险准备 | - | - | 0 | - |
| 未分配利润 | 4,373,734,412.6 | 4,382,997,688.87 | 4,405,096,938.51 | 4,396,010,336.09 |
| 归属于母公司股东权益平衡项目 | 0 | 0 | 0 | 0 |
| 归属于母公司股东权益合计 | 5,807,125,824.33 | 5,826,392,063.9 | 5,888,448,333.17 | 5,898,595,850.24 |
| 少数股东权益 | 192,543,190.19 | 192,285,376.12 | 221,873,823.74 | 230,057,380.64 |
| 股东权益平衡项目 | 0 | 0 | 0 | 0 |
| 股东权益合计 | 5,999,669,014.52 | 6,018,677,440.02 | 6,110,322,156.91 | 6,128,653,230.88 |
| 负债和股东权益合计 | 6,499,402,061.63 | 6,593,078,595.9 | 6,829,941,182.42 | 6,933,422,004.03 |
| 公告日期 | 2025-04-30 | 2025-04-25 | 2024-10-31 | 2024-08-29 |
| 审计意见(境内) | | 标准无保留意见 | | |